PCSK9 inhibition – Ready for prime time?

Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH.

Sequence variations in PCSK9, low LDL, and protection

against coronary heart disease. N Engl J Med 2006 Mar

:354(12):1264–72.

Dadu RT, Ballantyne CM. Lipid lowering with PCSK9

inhibitors. Nat Rev Cardiol 2014 Oct: 11(10):563–75.

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G,

Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M,

Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U,

Kastelein JJ, ODYSSEY LONG TERM Investigators. N

Engl J Med 2015 Apr 16:372(16):1489–99.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom

DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J,

Wasserman SM, Scott R, Koren MJ, Stein EA; Open-label

study of long-term evaluation against LDL cholesterol

(osler) investigators. Efficacy and safety of evolocumab in

reducing lipids and cardiovascular events. N Engl J Med

April 16; 372(16):1500–9.

Sabatine MS, Giuglinao RP, Keech AC, Honarpour N,

Wiviott SC, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman

SM, Sever PS, Pederson TR; FOURIER Steering Committee

and Investigators. Evolocumab and clinical outcomes

in patients with cardiovascular disease. N. Engl J Med 2017

Mar 17. doi:10.1056/NEJMoa1615664.

4S group. Randomized trial of cholesterol lowering in

patients with coronary heart disease: the Scandinavian

Simvastatin Survival Study (4S). Lancet 1994 Nov 19;

(8934):1383–9.

Long-Term Intervention with Pravastatin in Ischemic Disease

(LIPID) Study Group. Prevention of cardiovascular

events and death with pravastatin in patients with coronary

heart disease and a broad range of initial cholesterol levels.

N Engl J Med 1998 Nov 5; 339(19):1349–57.

Sacks FM, Pfeffer MA, Moyle LA, Rouleau JL, Rutherford

JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun

CC, Davis BR, Braunwald E. The effect of pravastatin

on coronary events after myocardial infarction in patients

with average cholesterol levels. Cholesterol and Recurrent

Events Trial investigators. N Engl J Med 1996 Oct

:335(14):1001–9.

Heart Protection Study Collaborative Group. MRC/BHF

Heart Protection Study of cholesterol lowering with simvastatin

in 20,536 high-risk individuals: a randomized placebocontrolled

trial. Lancet 2002 Jul 6:360(9326):7–22.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR,

MacFarlane PW, Mckillop JH, Packard CJ. Prevention of

coronary heart disease with pravastatin in men with hypercholesterolemia.

West of Scotland Coronary Prevention

Study Group. N Engl J Med 1995 Nov 16; 333(20):1301–7.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR,

Beere PA, Langendorder A, Stein EA, Kruyer W, Gotto

AM Jr. Primary prevention of acute coronary events with

lovastatin in men and women with average cholesterol levels:

results of AFCAPS/TexCAPS. Airforce/Texas CoronaryAtherosclerosis

Prevention Study. JAMA 1998 May 27; 279(20):1615–22.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM

Jr, Kastelein JJ, Koenig W, Libby P, Lorezatti AJ, MacFadyen

JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ;

JUPITER Study Group. Rosuvastatin to prevent vascular

events in men and women with elevated C-reactive protein.

N Engl J Med 2008 Nov 20; 359(21):2195–207.

Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai

G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr,

Waksman R. The impact of proprotein convertase subtilisin-

kexin type 9 serine protease inhibitors on lipid levels and

outcomes in patients with primary hypercholesterolemia: a

network meta-analysis. Eur Heart J 2016 Feb 7; 37(6):536–45.

American College of Cardiology – 66th Annual Scientific

Sessions; Late Breaking Clinical Trial. March 18, 2017.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz

R, Goodman SG, Hanotin C, Harrington RA, Jukema JW,

Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela

WJ, Shirodaria C, Szarek M, Tamby Jf, Tricoci P, White H, Zeiher

A, Steg PG. Effect of alirocumab, a monoclonal antibody to

PCSK9, on long-term cardiovascular outcomes following acute

coronary syndromes: rational and design of the ODYSSEY outcomes

trial. Am Heart J 2014 Nov; 168(5):682–9.

Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ,

Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S,

Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL,

Yunis CL, SPIRE Investigators. Lipid-reduction variability

and antidrug-antibody formation with Bococizumab. N Engl

J Med 2017 April 20; 376(16):1517–1526.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour

R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL,

Wijngaard P, Wright RS, Kastelein JJ. Inclisiran in patients

at high cardiovascular risk with elevated LDL cholesterol. N

Engl J Med 2017 Apr 13; 376(15):1430–40. doi: 10.1056/

NEJMoa1615758.